Search Result

Results for "

Src

" in MCE Product Catalog:

By Targets:	Src (89) 5-HT Receptor (1) Akt (2) Antibiotic (1) Apoptosis (31) Aurora Kinase (3) Autophagy (13) Bacterial (1) Bcr-Abl (20) BCRP (1) Btk (2) c-Fms (1) c-Kit (7) c-Met/HGFR (2) c-Myc (1) CaMK (2) COX (2) Cytochrome P450 (1) Drug Metabolite (4) EGFR (9) ERK (1) Estrogen Receptor/ERR (1) FAK (3) FGFR (14) FLT3 (3) FXR (1) G-quadruplex (3) HIV (1) IGF-1R (1) IKK (1) Isotope-Labeled Compounds (1) JAK (5) JNK (1) LIM Kinase (LIMK) (1) LXR (1) MAP3K (1) Microtubule/Tubulin (3) MMP (1) MNK (1) mTOR (1) NF-κB (2) NO Synthase (1) p38 MAPK (5) PAK (1) Parasite (1) PDGFR (15) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (2) PKA (2) PKC (3) Polo-like Kinase (PLK) (1) Prostaglandin Receptor (1) Raf (4) Reactive Oxygen Species (1) RET (2) Ribosomal S6 Kinase (RSK) (2) ROR (1) STAT (7) Syk (3) TGF-β Receptor (1) Topoisomerase (1) VEGFR (16) Wnt (1)
By Research Areas:	Cancer (112) Cardiovascular Disease (2) Endocrinology (2) Infection (3) Inflammation/Immunology (20) Metabolic Disease (3) Neurological Disease (3)

By Targets:

Src (89)

5-HT Receptor (1)

Akt (2)

Antibiotic (1)

Apoptosis (31)

Aurora Kinase (3)

Autophagy (13)

Bacterial (1)

Bcr-Abl (20)

BCRP (1)

Btk (2)

c-Fms (1)

c-Kit (7)

c-Met/HGFR (2)

c-Myc (1)

CaMK (2)

COX (2)

Cytochrome P450 (1)

Drug Metabolite (4)

EGFR (9)

ERK (1)

Estrogen Receptor/ERR (1)

FAK (3)

FGFR (14)

FLT3 (3)

FXR (1)

G-quadruplex (3)

HIV (1)

IGF-1R (1)

IKK (1)

Isotope-Labeled Compounds (1)

JAK (5)

JNK (1)

LIM Kinase (LIMK) (1)

LXR (1)

MAP3K (1)

Microtubule/Tubulin (3)

MMP (1)

MNK (1)

mTOR (1)

NF-κB (2)

NO Synthase (1)

p38 MAPK (5)

PAK (1)

Parasite (1)

PDGFR (15)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

PI3K (2)

PKA (2)

PKC (3)

Polo-like Kinase (PLK) (1)

Prostaglandin Receptor (1)

Raf (4)

Reactive Oxygen Species (1)

RET (2)

Ribosomal S6 Kinase (RSK) (2)

ROR (1)

STAT (7)

Syk (3)

TGF-β Receptor (1)

Topoisomerase (1)

VEGFR (16)

Wnt (1)

By Research Areas:

Cancer (112)

Cardiovascular Disease (2)

Endocrinology (2)

Infection (3)

Inflammation/Immunology (20)

Metabolic Disease (3)

Neurological Disease (3)

138

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Src SHP2

Cat. No.	Product Name	Target	Research Areas

HY-101053

Src Inhibitor 1 Src Kinase Inhibitor 1; Src-l1	Src	Cancer
Src Inhibitor 1 is a potent, ATP-competitive and selective dual site *Src* tyrosine kinase inhibitor with IC₅₀ values of 44 nM for Src and 88nM for Lck.

HY-130254

Src Inhibitor 3	Src	Cancer Inflammation/Immunology
Src Inhibitor 3 is a potent, orally active *c-terminal Src* kinase (CSK) with IC₅₀** values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively. Src Inhibitor 3 shows the ability to increase T cell proliferation induced by T cell receptor signaling.

HY-108488

*KB SRC* 4**	Src	Cancer
KB SRC 4 is a potent, and highly selective *c-Src* inhibitor, with a K_i of 44 nM and a K_d of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.

HY-P0200

RR-SRC
Src Inflammation/Immunology

RR-SRC is a substrate for src-tyrosine-specific protein kinase.
HY-16905

T338C Src-IN-1
Src Cancer

T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase).
HY-P3773

p60c-src substrate II
Src Cancer

p60c-src substrate II is an efficient pentapeptide substrate for the tyrosine kinase pp60c-src.

RR-SRC	Src	Inflammation/Immunology
RR-SRC is a substrate for src-tyrosine-specific protein kinase.

*T338C Src-IN-1*	Src	Cancer
T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase).

*p60c-src* substrate II**	Src	Cancer
p60c-src substrate II is an efficient pentapeptide substrate for the tyrosine kinase *pp60c-src*.

HY-12299

WH-4-023 Dual LCK/Src inhibitor	Src	Cancer
WH-4-023 is a potent and selective dual *Lck/Src* inhibitor with IC₅₀ of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.

HY-P2548

*pp60 (v-SRC) Autophosphorylation Site, Phosphorylated*	EGFR	Others
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification.

HY-16906

T338C Src-IN-2
Src Cancer

T338C Src-IN-2 is a potent mutant c-Src T338C kinase inhibitor with IC50 of 317 nM; also inhibits T338C/V323A and T338C/V323S with IC50 of 57 nM/19 nM.

*T338C Src-IN-2*	Src	Cancer
T338C Src-IN-2 is a potent mutant c-Src T338C kinase inhibitor with IC50 of 317 nM; also inhibits T338C/V323A and T338C/V323S with IC50 of 57 nM/19 nM.

HY-W062835

CGP77675	Src	Cancer
CGP77675 is an orally active and potent inhibitor of *Src* family kinases. CGP77675 inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC₅₀s of 5-20 and 40 nM, respectively), and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC₅₀s of 5-20, 40, 20, 150, 1000, 310, and 290 nM, respectively. Anticancer activity.

HY-15176

Pyridostatin RR82	G-quadruplex	Cancer
Pyridostatin (RR82) is a G-quadruplex DNA stabilizing agent (K_d=490 nM). Pyridostatin promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin targets the proto-oncogene Src. Pyridostatin reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells.

HY-15176A

Pyridostatin hydrochloride RR82 hydrochloride	G-quadruplex	Cancer
Pyridostatin (RR82) hydrochloride is a G-quadruplex DNA stabilizing agent (K_d=490 nM). Pyridostatin hydrochloride promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin hydrochloride targets the proto-oncogene Src. Pyridostatin hydrochloride reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells.

HY-W062835A

CGP77675 hydrate	Src	Cancer
CGP77675 hydrate is an orally active and potent inhibitor of *Src* family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC₅₀s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC₅₀s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity.

HY-15176B

Pyridostatin TFA RR82 TFA	G-quadruplex	Cancer
Pyridostatin (RR82) TFA is a G-quadruplex DNA stabilizing agent (K_d=490 nM). Pyridostatin TFA promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage. Pyridostatin TFA targets the proto-oncogene Src. Pyridostatin TFA reduced SRC protein levels and SRC-dependent cellular motility in human breast cancer cells.

HY-136605

DGY-06-116
Src Cancer

DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC₅₀ of 3nM. DGY-06-116 inhibits FGFR1 with an IC₅₀ of 8340 nM.

DGY-06-116	Src	Cancer
DGY-06-116 is an irreversible covalent, selective *Src* inhibitor with an IC₅₀ of 3nM. DGY-06-116 inhibits FGFR1 with an IC₅₀ of 8340 nM.

HY-108486

Herbimycin A	Bacterial Antibiotic	Infection
Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60^v-src and p210^BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.

HY-147314

HIV-IN-6
HIV Src Infection

HIV-IN-6 is a HIV-Ⅰ viral replication inhibitor by targeting Src family kinases (SFK) that interact with Nef protein of the virus, such as Hck.

HIV-IN-6	HIV Src	Infection
HIV-IN-6 is a HIV-Ⅰ viral replication inhibitor by targeting Src family kinases (SFK) that interact with Nef protein of the virus, such as Hck.

HY-12047

Ponatinib AP24534	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and *Src*, respectively.

HY-108766

Ponatinib hydrochloride AP24534 hydrochloride	Bcr-Abl FGFR PDGFR VEGFR Src Autophagy	Cancer
Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and *Src*, respectively.

HY-12047S

Ponatinib-d8 AP24534-d₈	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib-d₈ is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-135299

CH6953755	Src	Cancer
CH6953755 is a potent, orally active and selective YES1 kinase (a member of the SRC family) inhibitor with an IC₅₀ of 1.8 nM. CH6953755 inhibits YES1 kinase, leading to antitumor activity against YES1 Gene -amplified cancers in vitro and in vivo.

HY-N2521

Tetramethylcurcumin FLLL31	STAT Apoptosis	Cancer Inflammation/Immunology
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects.

HY-N1381

Periplocin	Apoptosis	Cancer Inflammation/Immunology
Periplocin is a cardiotonic steroid isolated from root-bark Periploca sepium Bunge. Periplocin promotes tumor cell apoptosis and inhibits tumor growth. Periplocin has the potential to facilitate wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase.

HY-120200

YF-452	VEGFR	Cancer Cardiovascular Disease
YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic drug candidate for cancer research.

HY-108417

Debio 0617B	STAT JAK Bcr-Abl	Cancer
Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34⁺ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors.

HY-10395

PD173955
Bcr-Abl Src Apoptosis Cancer

PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for for Src, Yes and Abl kinase.

PD173955	Bcr-Abl Src Apoptosis	Cancer
PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for for Src, Yes and Abl kinase.

HY-15764A

A 419259 trihydrochloride RK 20449 trihydrochloride	Src	Cancer
A 419259 trihydrochloride is a Src family kinases inhibitor with IC₅₀s of 9 nM, 3 nM and 3 nM for *Src, Lck* and Lyn, respectively.

HY-139890

DC-Srci-6649
Src Others

DC-Srci-6649 is a c-Src kinase inhibitor that inhibits the phosphorylation and locks c-Src in the inactive state.
HY-10363

AP 24149
Bcr-Abl Src Cancer

AP 24149 is a potent Src-Abl dual inhibitor with IC₅₀ values of 9.1, 3.6 nM for Src and Abl, respectively.

DC-Srci-6649	Src	Others
DC-Srci-6649 is a *c-Src* kinase inhibitor that inhibits the phosphorylation and locks c-Src in the inactive state.

AP 24149	Bcr-Abl Src	Cancer
AP 24149 is a potent *Src-Abl* dual inhibitor with IC₅₀ values of 9.1, 3.6 nM for Src and Abl, respectively.

HY-10340B

Tirbanibulin Mesylate KX2-391 Mesylate; KX01 Mesylate	Src Microtubule/Tubulin	Cancer
Tirbanibulin Mesylate (KX2-391 Mesylate) is an inhibitor of *Src* that targets the peptide substrate site of Src, with GI₅₀ of 9-60 nM in cancer cell lines.

HY-10340

Tirbanibulin KX2-391; KX-01	Src Microtubule/Tubulin	Cancer
Tirbanibulin (KX2-391) is an inhibitor of *Src* that targets the peptide substrate site of Src, with GI₅₀ of 9-60 nM in cancer cell lines.

HY-10340A

Tirbanibulin dihydrochloride KX2-391 dihydrochloride; KX-01 dihydrochloride	Src Microtubule/Tubulin	Cancer
Tirbanibulin (dihydrochloride) (KX2-391 (dihydrochloride)) is an inhibitor of *Src* that targets the peptide substrate site of Src, with GI₅₀ of 9-60 nM in cancer cell lines.

HY-19625

MCB-613	Reactive Oxygen Species	Cancer
MCB-613 is a potent Steroid receptor coactivator *SRC* small molecule ‘stimulator’ (SMS), super-stimulates SRCs’ transcriptional activity. MCB-613 increases SRCs’ interactions with other coactivators and markedly induces ER stress coupled to the generation of reactive oxygen species (ROS). MCB-613 is a SMS that target oncogenes can be exploited as anti-cancer agents by over-stimulating the SRC oncogenic program.

HY-15764

A 419259 RK-20449	Src	Cancer
A 419259 is a broad-spectrum pyrrolo-pyrimidine inhibitor, designed to enhance selectivity towards the Src family with IC₅₀ of 9 nM, <3 nM and <3 nM for *Src, Lck* and Lyn, respectively.

HY-139147

iHCK-37 ASN05260065	Src	Cancer Infection
iHCK-37 (ASN05260065) is a potent and specific Hck inhibitor with a K_i value of 0.22 μM. iHCK-37 blocks HIV-1 viral replication with an EC₅₀ value of 12.9 μM. iHCK-37 is used for chronic myeloid leukemia (CML) research.

HY-111787

Elzovantinib TPX-0022; CSF1R-IN-2	Src c-Met/HGFR c-Fms	Cancer
Elzovantinib (TPX-0022) is an oral-active inhibitor of *SRC, MET* and c-FMS, with IC₅₀ values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.

HY-P3279

EPQpYEEIPIYL	Src	Cancer
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains.

HY-10181B

Dasatinib monohydrate BMS-354825 monohydrate	Bcr-Abl Src Autophagy Apoptosis	Cancer
Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual *Src/Bcr-Abl* inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and *Src* with IC₅₀s of <1.0 nM and 0.5 nM, respectively. Dasatinib monohydrate also induces apoptosis and autophagy.

HY-10181A

Dasatinib hydrochloride BMS-354825 hydrochloride	Bcr-Abl Src Autophagy Apoptosis	Cancer
Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual *Src/Bcr-Abl* inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and *Src* with IC₅₀s of <1.0 nM and 0.5 nM, respectively. Dasatinib hydrochloride also induces apoptosis and autophagy.

HY-10181

Dasatinib BMS-354825	Bcr-Abl Src Autophagy Apoptosis	Cancer
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual *Src/Bcr-Abl* inhibitor with potent antitumor activity. The K_is are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and *Src* with IC₅₀s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.

HY-N6596

7-Hydroxy-4-chromone
7-Hydroxychromone
Src Cancer

7-Hydroxychromone is a Src kinase inhibitor with an IC₅₀ of <300 μM.

7-Hydroxy-4-chromone 7-Hydroxychromone	Src	Cancer
7-Hydroxychromone is a Src kinase inhibitor with an IC₅₀ of <300 μM.

HY-101268

CHMFL-ABL-053	Bcr-Abl Src p38 MAPK	Cancer
CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available BCR-ABL, *SRC* and p38 kinase inhibitor with IC₅₀ values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively.

HY-127002A

Squarunkin A hydrochloride	Src	Cancer
Squarunkin A hydrochloride is a potent and selective UNC119-cargo interaction inhibitor (IC₅₀ of 10 nM for inhibiting the *UNC119A-myristoylated Src* N-terminal peptide interaction*). Squarunkin A hydrochloride interferes with the activation of Src* kinase in cells.

HY-10234

Saracatinib AZD0530	Src Autophagy	Cancer
Saracatinib (AZD0530) is a potent *Src* family inhibitor with IC₅₀s of 2.7 to 11 nM for *c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk*. Saracatinib shows high selectivity over other tyrosine kinases.

HY-127002

Squarunkin A	Src	Cancer
Squarunkin A is a potent and selective UNC119-cargo interaction inhibitor, interrupting the UNC119A-myristoylated Src N-terminal peptide interaction (IC₅₀=10 nM). Squarunkin A interferes with the activation of Src kinase in cells.

HY-112800

cyt-PTPε Inhibitor-1	Phosphatase	Metabolic Disease
cyt-PTPε Inhibitor-1 is a potent cytosolic protein tyrosine phosphatase epsilon (cyt-PTPε) inhibitor, binds to the catalytic domain of cyt-PTPε, blocks c-Src activation (dephosphorylation of c-Src), and exhibits anti-osteoclastic activity.

HY-13942

1-NM-PP1 PP1 Analog II	Src	Cancer
1-NM-PP1, a cell-permeable PP1 analog, is a potent Src family kinases inhibitor with IC₅₀s of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively.

HY-101447A

SI-2 hydrochloride EPH 116 hydrochloride	Others	Cancer
SI-2 (EPH 116 hydrochloride) is a highly promising *SRC-3* inhibitor (PPI), with IC₅₀ values of 3-20 nM for breast cancer cell death. SI-2 (EPH 116 hydrochloride) has a much improved toxicity and pharmacokinetic profile, with acceptable oral availability.

HY-P2547

Tyrosine Kinase Peptide 1
Src Others

Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay.

HY-136541

YB-0158 Wnt pathway inhibitor 2	Wnt Apoptosis	Cancer
YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities.

HY-B0789

SU6656	Src FAK Akt	Cancer
SU6656 is a Src family kinases inhibitor with IC₅₀s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.

HY-10158A

Bosutinib hydrate
SKI-606 hydrate
Src Bcr-Abl

Bosutinib (hydrate) is an oral Src/Abl tyrosine kinase inhibito with IC₅₀ of 1.2 nM and 1 nM, respectively.
HY-10158

Bosutinib
SKI-606
Src Bcr-Abl Autophagy Cancer

Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC₅₀ of 1.2 nM and 1 nM, respectively.
HY-13804

PP1
AGL 1872; EI 275
Src Apoptosis Cancer

PP1 is a potent, and Src family-selective tyrosine kinase inhibitor with IC₅₀ of 5 and 6 nM for Lck and Fyn, respectively.
HY-10181S

Dasatinib-d8
BMS-354825-d₈
Bcr-Abl Src Apoptosis Autophagy Cancer

Dasatinib-d₈ is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.

HY-136848

SM1-71	MAP3K Src FGFR Ribosomal S6 Kinase (RSK) LIM Kinase (LIMK)	Cancer
SM1-71 (compound 5) is a potent TAK1 inhibitor, with a K_i of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, *SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1* and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines.

HY-13941B

1-Naphthyl PP1 hydrochloride 1-NA-PP 1 hydrochloride	Src	Cancer
1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of *src* family kinases. 1-Naphthyl PP1 hydrochloride inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC₅₀s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively.

HY-13941

1-Naphthyl PP1 1-NA-PP 1	Src	Cancer
1-Naphthyl PP1 (1-NA-PP 1) is a selective inhibitor of *src* family kinases. 1-Naphthyl PP1 inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC₅₀s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively.

HY-123402

GSK3987	LXR	Metabolic Disease
GSK3987 is a pan LXRα/β agonist with EC₅₀s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation.

HY-13561

AZM475271
M475271
Src Cancer

AZM475271 is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2.
HY-112096

eCF506
Src Cancer

eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase Src with an IC₅₀ of less than 0.5 nM.
HY-13805

PP2
AGL 1879
Src Cancer

PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC₅₀s of 4 and 5 nM for Lck and Fyn, respectively.

HY-136895

AZ12672857	Prostaglandin Receptor	Cancer
AZ12672857 is an orally active inhibitor of EphB4 (IC₅₀=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC₅₀=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC₅₀=9 nM).

HY-139562

BMS-986318	FXR	Metabolic Disease
BMS-986318 is a potent nonbile acid FXR agonist with EC₅₀s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis.

HY-133794

Dasatinib N-oxide
Drug Metabolite Cancer

Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor.
HY-115723

Antiallergic agent-1
Src Inflammation/Immunology

Antiallergic agent-1, a Src-family kinase inhibitor, may serve as a new valuable lead compound for future antiallergic drug discovery.

HY-10185

TG 100572 Hydrochloride	Src VEGFR FGFR PDGFR	Inflammation/Immunology
TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10184

TG 100572	Src VEGFR PDGFR FGFR	Cancer
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-11011

A-770041	Src	Inflammation/Immunology
A-770041 is a selective and orally active Src-family Lck inhibitor. A-770041 inhibits Lck with an IC₅₀ value of 147 nM with the presence of 1 mM ATP. A-770041 shows 300-fold selective to Lck over Fyn, the other Src family kinase involved in T-cell signaling. A-770041 can be used for the research of acute rejection.

HY-18507

AD57
RET Raf Ribosomal S6 Kinase (RSK) Src Cancer

AD57 is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src, with greatly reduces mTOR activity.
HY-18622

PP58
Src FGFR PDGFR Cancer

PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC₅₀ values.

HY-P1200

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH	Src	Cancer
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC₅₀≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for src SH3-SH2:phosphoprotein interactions.

HY-10372

PP121
mTOR PDGFR VEGFR Src Apoptosis Cancer

PP121 is a multi-targeted kinase inhibitor with IC₅₀s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, VEGFR2, Src, PDGFR, respectively.

HY-10158S

Bosutinib D8 SKI-606-d₈	Src Bcr-Abl Autophagy	Cancer
Bosutinib-d₈ is a deuterium labeled Bosutinib. Bosutinib is a dual Src/Abl inhibitor with IC50s of 1.2 nM and 1 nM, respectively[1][2].

HY-117819

TMP920
ROR Inflammation/Immunology

TMP920 is a highly potent and selective RORγt antagonist. TMP920 inhibits RORγt binding to the SRC1 peptide with an IC₅₀ of 0.03 μM.

HY-P1200A

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA	Src	Cancer
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC₅₀≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for src SH3-SH2:phosphoprotein interactions.

HY-121418

Lusianthridin	c-Myc	Cancer
Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling.

HY-118144

PD166326	BCRP Src	Cancer
PD166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases, with IC₅₀s of 6 nM and 8 nM for *Src* and Abl, respectively. PD166326 exhibits antileukemic activity.

HY-N4127

3'-Demethylnobiletin	Src STAT	Cancer
3'-Demethylnobiletin, a derivative of Nobiletin, is a polymethoxyflavonoid in citrus fruits. Nobiletin exhibits anticancer activity and inhibits tumor angiogenesis by regulating Src, FAK, and STAT3 signaling.

HY-112182

UM-164
DAS-DFGO-II
Src p38 MAPK Autophagy Cancer

UM-164 (DAS-DFGO-II) is a highly potent inhibitor of c-Src with a K_d of 2.7 nM. UM-164 also potently inhibits p38α and p38β.

HY-10187

TG 100801 Hydrochloride	VEGFR FGFR PDGFR Src	Cancer
TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10186

TG 100801	VEGFR FGFR PDGFR Src	Cancer
TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-112314

AZD0424	Src Bcr-Abl Apoptosis	Cancer
AZD0424 is an orally active, and dual selective *Src/Abl* kinase inhibitor with potential antineoplastic activity. AZD0424 induces apoptosis and cell cycle arrest in lymphoma cells.

HY-131669

Dasatinib metabolite M6 Dasatinib carboxylic acid	Drug Metabolite	Others
Dasatinib metabolite M6 (Dasatinib carboxylic acid) is an oxidative metabolite of Dasatinib (HY-10181). Dasatinib is a potent and orally active dual Bcr-Abl and Src family tyrosine kinase inhibitor.

HY-10321

PD173074	FGFR VEGFR Apoptosis	Cancer
PD173074 is a potent FGFR1 inhibitor with an IC₅₀ of 25 nM and also inhibits VEGFR2 with an IC₅₀ of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.

HY-123506

Fenlean	Src	Inflammation/Immunology Neurological Disease
Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models.

HY-15749

XL228	Aurora Kinase Bcr-Abl IGF-1R Src	Cancer Endocrinology
XL228 is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, *Src* and Lyn, respectively.

HY-133794S

Dasatinib N-oxide-d8	Drug Metabolite	Cancer
Dasatinib N-oxide-d₈ is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor[1][2].

HY-32718

Pelitinib EKB-569; WAY-EKB 569	EGFR Src	Cancer
Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC₅₀ of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC₅₀s of 282, 800, and 1255 nM, respectively.

HY-P1784

Secretin, canine	Src	Endocrinology
Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway.

HY-12068

PI3K-IN-1
XL-147 derivative 1
PI3K Cancer

PI3K-IN-1 (XL-147 derivative 1) is a potent inhibitor of PI3K. PI3K-IN-1 (25 μM) blocks PI3K/Akt signaling pathways.

HY-10520

CGP 57380	MNK Apoptosis	Cancer
CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 with IC₅₀ of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.

HY-18237

KX1-004	Src	Others
KX1-004 is a potent and non-ATP competitive *Src-PTK* inhibitor with an IC₅₀ of 40 μM. KX1-004 protects the cochlea from hazardous noise and prevents noise-induced hearing loss (NIHL).

HY-N0896

Inulicin 1-O-Acetylbritannilactone	NF-κB COX	Cancer Inflammation/Immunology
Inulicin (1-O-Acetylbritannilactone) is an active compound that inhibits VEGF-mediated activation of *Src* and FAK. Inulicin (1-O-Acetylbritannilactone) inhibits LPS-induced PGE₂ production and COX-2 expression, and NF-κB activation and translocation.

HY-101219

VEGFR-IN-1	VEGFR c-Kit EGFR	Cancer
VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC₅₀s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively.

HY-18832

AWL-II-38.3	Others	Cancer
AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf.

HY-113960

ERRα antagonist-1	Estrogen Receptor/ERR	Cancer
ERRα antagonist-1 (Compound A) is a selective and high affinity estrogen-related receptor α (ERRα) antagonist. ERRα antagonist-1 inhibits interaction of ERRα with Proliferator-activated Receptor γ Coactivator-1α (PGC-1α) and PGC-1β, the IC₅₀ values are 170 nM and 180 nM, respectively. ERRα antagonist-1 does not inhibit the interaction of either ERRβ or ERRγ with PGC-1α and PGC-1β coactivator, and also does not inhibit interaction of ERα or ERβ with PGC-1α or SRC-1.

HY-107447

N-Deshydroxyethyl Dasatinib N-Deshydroxyethyl BMS-354825	Drug Metabolite	Cancer Inflammation/Immunology
N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825) is a metabolite of Dasatinib, Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. N-Deshydroxyethyl Dasatinib can be used in cancer and immune disease research.

HY-10542

GW 5074	Raf Apoptosis	Cancer
GW 5074 is a potent and selective c-Raf inhibitor with IC₅₀ of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms.

HY-18009

LFM-A13	Btk Polo-like Kinase (PLK) JAK	Cancer
LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.

HY-W013857

Lavendustin C	CaMK EGFR Src	Cancer
Lavendustin C is a potent Ca²⁺ calmodulin-dependent kinase II (CaMK II) inhibitor with an IC₅₀ of 0.2 µM. Lavendustin C inhibits EGFR-associated tyrosine kinase (IC₅₀=0.012 µM) and pp60^c-src(+) kinase (IC₅₀=0.5 µM) .

HY-112852A

TL02-59 dihydrochloride	Src Apoptosis	Cancer
TL02-59 dihydrochloride is an orally active, selective Src-family kinase Fgr inhibitor with an IC₅₀ of 0.03 nM. TL02-59 dihydrochloride inhibits Lyn and Hck with IC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 dihydrochloride potently suppresses acute myelogenous leukemia (AML) cell growth.

HY-112852

TL02-59	Src Apoptosis	Cancer
TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC₅₀ of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth.

HY-125035

LCH-7749944 GNF-PF-2356	PAK Apoptosis	Cancer
LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor with an IC₅₀ of 14.93 μM. LCH-7749944 effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclin D1 pathway and induces apoptosis.

HY-13024

Rebastinib DCC-2036	Bcr-Abl FLT3 Src Apoptosis	Cancer
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1^WT and Abl1^T315I with IC₅₀s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.

HY-10987A

ENMD-2076	Aurora Kinase FLT3 VEGFR FGFR PDGFR Src Apoptosis	Cancer
ENMD-2076 is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, *Src, PDGFRα*, respectively.

HY-12847

CCT241161	Raf Src Apoptosis	Cancer
CCT241161 is an orally active pan-RAF inhibitor with IC₅₀s of 3, 6, 10, 15 and 30 nM for LCK, CRAF, *SRC, V600E-BRAF* and BRAF, respectively. CCT241161 shows good activity to in BRAF and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity.

HY-18307

SYN1143	c-Met/HGFR	Cancer
SYN1143 is a potent, selective and orally active dual inhibitor of c-Met/RON, with IC₅₀s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, Tie2, *Src, and BTK* with IC₅₀s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated.

HY-10987

ENMD-2076 Tartrate	Aurora Kinase FLT3 VEGFR FGFR Src PDGFR Apoptosis	Cancer
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, *Src, PDGFRα*, respectively.

HY-18302

c-Kit-IN-5-1	c-Kit	Inflammation/Immunology
c-Kit-IN-5 is potent inhibitor of c-Kit, with IC₅₀s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties.

HY-107595

SD-1008	JAK STAT Apoptosis	Cancer
SD-1008 is a potent JAK inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances apoptosis induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway.

HY-100338

CNX-500	Btk	Cancer
CNX-500 is a probe consisting of a covalent Btk inhibitor (CC-292) chemically linked to biotin. CNX-500 retains inhibitory activity against Btk (IC₅₀ of 0.5 nM) and the ability to form a covalent bond with Btk. CNX-500 has low inhibitory effects on kinase epidermal growth factor receptor, and upstream Src-family kinases including Syk and Lyn.

HY-10230S

Midostaurin-d5 PKC412-d₅; CGP 41251-d₅	Isotope-Labeled Compounds PKC Syk Akt PKA c-Kit	Cancer
Midostaurin-d₅ is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM[1].

HY-120595

JNJ-49095397 RV568	p38 MAPK Src	Inflammation/Immunology
JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma.

HY-12072

Lck Inhibitor	Src	Inflammation/Immunology
Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC₅₀s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis.

HY-103094

LY266097 hydrochloride	5-HT Receptor	Inflammation/Immunology
LY266097 hydrochloride is a selective 5-HT2B receptor antagonist with pK_is of 7.7, 9.8, and 7.6 for 5-HT2A, 5-HT2B, 5-HT2C, respectively. 5-HT2B receptor blockade contributes to the research in depression.

HY-112386

OXSI-2
Syk Inflammation/Immunology

OXSI-2 is a bioavailable, cell-permeable Syk inhibitor with an EC₅₀ of 313 nM and an IC₅₀ of 14 nM.

HY-103274

PD180970	Bcr-Abl Src c-Kit Apoptosis	Cancer Neurological Disease
PD180970 is a highly potent and ATP-competitive p210^Bcr-Abl kinase inhibitor, with an IC₅₀ of 5 nM for inhibiting the autophosphorylation of p210^Bcr-Abl. PD180970 also inhibits *Src* and KIT kinase with IC₅₀s of 0.8 nM and 50 nM, respectively. PD180970 indcues apoptosis of K562 leukemic cells, and can be used for chronic myelogenous leukemia research.

HY-N4201

β-Hydroxyisovalerylshikonin	EGFR Src	Cancer
Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermum erythrorhizon, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC₅₀s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells.

HY-121828

TX-1123	Src CaMK PKA EGFR PKC COX	Cancer
TX-1123 is a potent protein tyrosine kinase (PTK) inhibitor for Src, eEF2-K, and PKA, and EGFR-K/PKC. TX-1123 is a cyclo-oxygenase (COX) inhibitor with IC₅₀ values of 1.16 μM and 15.7 μM for COX2 and COX1, respectively. TX-1123 has low mitochondrial toxicity. TX-1123 can be used in research of cancer.

HY-N0498

Nitidine chloride	Parasite Apoptosis STAT Topoisomerase ERK FAK p38 MAPK NF-κB	Cancer Inflammation/Immunology
Nitidine chloride, a potential anti-malarial lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing apoptosis, inhibiting STAT3 signaling cascade, DNA topoisomerase 1 and 2A, ERK and *c-Src/FAK* associated signaling pathway. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kB pathway.

HY-135366

HPN-01	IKK	Inflammation/Immunology
HPN-01 is a potent and selective IKK inhibitor, with pIC₅₀ values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2.

HY-107779

BI-882370	Raf	Cancer
BI-882370 is a potent and selective RAF kinase inhibitor that binds to the ATP binding site of the kinase positioned in the DFG-out (inactive) conformation of the BRAF kinase. BI-882370 (BI 882370) inhibits the oncogenic BRAF^V600E-mutant, the WT BRAF and CRAF kinases with IC₅₀s of 0.4, 0.8, and 0.6 nM, respectively. BI-882370 also inhibits SRC family kinases.

HY-16558

Butein 2’,3,4,4’-tetrahydroxy Chalcone	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Cancer
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4. Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60^c-src in HepG2 cells. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Butein is a SIRT1 activator (STAC).

HY-78263

MNS NSC 170724; 5-(2-Nitrovinyl)benzodioxole	Src Syk	Cancer
MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC₅₀ values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS inhibits Src, Syk, and FAK with IC₅₀ of 27.3, 2.8, and 97.6 μM, respectively.

HY-18303

AMG-47a	Src VEGFR p38 MAPK JAK	Inflammation/Immunology
AMG-47a is a potent and orally active lymphocyte-specific protein tyrosine kinase (Lck) inhibitor, with an IC₅₀ of 0.2 nM. AMG-47a also inhibits VEGF2, p38α, Jak3 and MLR and IL-2 with IC₅₀s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively. AMG-47a has anti-inflammatory activity.

HY-107024

Osteogenic Growth Peptide (10-14) OGP(10-14); Historphin	Src	Others
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a *Src* inhibitor.

HY-152079

CYP1B1-IN-3	Cytochrome P450	Cancer
CYP1B1-IN-3 is a potent and selective CYP1B1 inhibitor with IC₅₀ values of 6.6, 347.3, >10000 nM for CYP1B1, CYP1A1, CYP1A2, respectively. CYP1B1-IN-3 inhibits cell migration and invasion. CYP1B1-IN-3 inhibits P-gp, AKT/ERK, FAK/SRC, and EMT pathways.

HY-10230

Midostaurin PKC412; CGP 41251	PKC VEGFR c-Kit NO Synthase Apoptosis	Cancer
Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, *c-Src, FLT3, PDFRβ* and VEGFR1/2 with IC₅₀s ranging from 22-500 nM. Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects.

HY-11010

AS601245	JNK	Cancer Inflammation/Immunology Neurological Disease
AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC₅₀s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties.

HY-112345

PD-089828	FGFR PDGFR EGFR Src	Cancer
PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC₅₀s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of *c-Src* tyrosine kinase (IC₅₀=0.18 µM). PD-089828 also inhibits MAPK with an IC₅₀ of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity.

HY-100434

PD-161570	FGFR PDGFR EGFR Src TGF-β Receptor	Cancer Cardiovascular Disease
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC₅₀ of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and *c-Src* tyrosine kinases with IC₅₀ values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC₅₀s of 450 nM and 622 nM, respectively. PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling** inhibitor.

HY-15814

HG-7-85-01	Bcr-Abl PDGFR c-Kit Src JAK Apoptosis	Cancer
HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR and RET with IC₅₀s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC₅₀>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression.

HY-149007

STAT3-IN-11	STAT Apoptosis	Cancer
STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers.

HY-120213

YH-306	FAK Src PI3K MMP Apoptosis	Cancer
YH-306 is an antitumor agent. YH-306 suppresses colorectal tumour growth and metastasis via FAK pathway. YH-306 significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell apoptosis. YH-306 suppresses the activation of FAK, c-Src, paxillin, and PI3K, Rac1 and the expression of MMP2 and MMP9. YH-306 also inhibita actin-related protein (Arp2/3) complex-mediated actin polymerization.

HY-123450

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies.

HY-151577

STAT3-SH2 domain inhibitor 1	STAT Apoptosis	Cancer
STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a K_d value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer.

HY-13342AS

Apatinib-d8 free base YN968D1-d₈ free base	Src VEGFR Autophagy c-Kit RET	Cancer
Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base[1]. Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the treatment of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[2][3][4].

Cat. No.	Product Name	Target	Research Area

HY-P2513

Src Optimal Peptide Substrate
Peptides Others

Src Optimal Peptide Substrate is a highly specific Src substrate. Src Optimal Peptide Substrate can used to measure the Src activity.
HY-P0200

RR-SRC
Src Inflammation/Immunology

RR-SRC is a substrate for src-tyrosine-specific protein kinase.

HY-P3743

*p60c-src* Substrate**	Peptides	Others
p60c-src Substrate is an efficient and specific substrate for *p60c-src* protein tyrosine kinase (PTK). p60c-src Substrate can be used to synthesize chimeric branched peptides.

HY-P3773

p60c-src substrate II
Src Cancer

p60c-src substrate II is an efficient pentapeptide substrate for the tyrosine kinase pp60c-src.

HY-P3744

*pp60v-src* Autophosphorylation site**	Peptides	Others
pp60v-src Autophosphorylation site is a synthetic peptide. pp60v-src Autophosphorylation site can be used for various biochemical studies.

HY-P2372

P60v-src(137-157)
Peptides Others

P60v-src(137-157) is a synthetic peptide that inhibits the tyrosine kinase activity of p60^v-src (IC₅₀: 7.5 μM).

HY-P3771

*p60c-src* substrate II, phosphorylated**	Peptides	Others
p60c-src substrate II, phosphorylated is a pentapeptide. p60c-src substrate II, phosphorylated is a p60c-src substrate II phosphorylated polypeptide. Protein phosphorylation is an important post-translationmodification of protein that is indispensible in biological regulations.

HY-P1199

*pp60 c-src* (521-533) (phosphorylated)**	Peptides	Others
pp60 c-src (521-533) (phosphorylated) is a peptide corresponding to the pp60c-src carboxy terminal regulatory domain, phosphorylated at Tyr527.

HY-P2548

*pp60 (v-SRC) Autophosphorylation Site, Phosphorylated*	EGFR	Others
pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification.

HY-P3279

EPQpYEEIPIYL	Src	Cancer
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains.

HY-P2547

Tyrosine Kinase Peptide 1
Src Others

Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay.

HY-P1200

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH	Src	Cancer
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC₅₀≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for src SH3-SH2:phosphoprotein interactions.

HY-P1200A

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA	Src	Cancer
Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC₅₀≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA is an inhibitor for src SH3-SH2:phosphoprotein interactions.

HY-P1784

Secretin, canine	Src	Endocrinology
Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway.

HY-107024

Osteogenic Growth Peptide (10-14) OGP(10-14); Historphin	Src	Others
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a *Src* inhibitor.

Cat. No.	Product Name	Target	Category

HY-108486

Herbimycin A	Bacterial Antibiotic	Quinones Benzene Quinones Structural Classification Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60^v-src and p210^BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.

HY-N2521

Tetramethylcurcumin FLLL31	STAT Apoptosis	Phenols Classification of Application Fields Disease Research Fields Inflammation/Immunology Source classification Plants other families
Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects.

HY-N1381

Periplocin	Apoptosis	Steroids Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Asclepiadaceae Periploca sepium Bunge
Periplocin is a cardiotonic steroid isolated from root-bark Periploca sepium Bunge. Periplocin promotes tumor cell apoptosis and inhibits tumor growth. Periplocin has the potential to facilitate wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase.

HY-N6596

7-Hydroxy-4-chromone 7-Hydroxychromone	Src	Phenols Monophenols Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Source classification Plants Celastraceae Tripterygium wilfordii Hook. f.
7-Hydroxychromone is a Src kinase inhibitor with an IC₅₀ of <300 μM.

HY-121418

Lusianthridin	c-Myc	Phenols Polyphenols Natural Products Classification of Application Fields Disease Research Fields Cancer Source classification Plants other families
Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling.

HY-N4127

3'-Demethylnobiletin	Src STAT	Monophenols Phenols Flavones Flavonoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Rutaceae Citrus
3'-Demethylnobiletin, a derivative of Nobiletin, is a polymethoxyflavonoid in citrus fruits. Nobiletin exhibits anticancer activity and inhibits tumor angiogenesis by regulating Src, FAK, and STAT3 signaling.

HY-N0896

Inulicin 1-O-Acetylbritannilactone	NF-κB COX	Sesquiterpenes Terpenoids Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Compositae Inula japonica
Inulicin (1-O-Acetylbritannilactone) is an active compound that inhibits VEGF-mediated activation of *Src* and FAK. Inulicin (1-O-Acetylbritannilactone) inhibits LPS-induced PGE₂ production and COX-2 expression, and NF-κB activation and translocation.

HY-N4201

β-Hydroxyisovalerylshikonin	EGFR Src	Quinones Naphthalene Quinones Phenols Polyphenols Disease Research Fields Cancer Classification of Application Fields Source classification Plants Boraginaceae Lithospermum erythrorhizon Sieb. et Zucc.
Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermum erythrorhizon, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC₅₀s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells.

HY-N0498

Nitidine chloride	Parasite Apoptosis STAT Topoisomerase ERK FAK p38 MAPK NF-κB	Isoquinoline Alkaloids Alkaloids Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Rutaceae Zanthoxylum nitidum (Roxb.) DC.
Nitidine chloride, a potential anti-malarial lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing apoptosis, inhibiting STAT3 signaling cascade, DNA topoisomerase 1 and 2A, ERK and *c-Src/FAK* associated signaling pathway. Nitidine chloride inhibits LPS-induced inflammatory cytokines production via MAPK and NF-kB pathway.

HY-16558

Butein 2’,3,4,4’-tetrahydroxy Chalcone	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)	Chalcones Phenols Polyphenols Flavonoids Disease Research Fields Cancer Anti-aging Classification of Application Fields Source classification Plants other families
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4. Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for EGFR and p60^c-src in HepG2 cells. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Butein is a SIRT1 activator (STAC).

Species:	Human (4) Mouse (4)
Tag:	His (5) Tag Free (1) GST (6)
Source:	HEK293 (1) Sf9 insect cells (2) Sf9 insect cells (5)

Cat. No.	Product Name	Species	Source

HY-P73422

Src Protein, Human (sf9, His-GST)
Proto-oncogene tyrosine-protein kinase Src; Src; p60-Src; Src1
Human Sf9 insect cells
HY-P73423

Src Protein, Mouse (sf9, His-GST)
Proto-oncogene tyrosine-protein kinase Src; Src; p60-Src; Src1
Mouse Sf9 insect cells
HY-P75470

Brk Protein, Human (sf9, GST)
Protein-tyrosine kinase 6; Src-related intestinal kinase; Ptk6; Sik
Human Sf9 insect cells
HY-P72856

Brk Protein, Mouse (sf9, His-GST)
Protein-tyrosine kinase 6; Src-related intestinal kinase; Ptk6; Sik
Mouse Sf9 insect cells
HY-P75322

CSK Protein, Mouse (sf9)
Tyrosine-protein kinase CSK; C-Src kinase; CSK
Mouse Sf9 insect cells
HY-P72956

CSK Protein, Human (sf9, GST)
Tyrosine-protein kinase CSK; C-Src kinase; CSK
Human Sf9 insect cells
HY-P72957

CSK Protein, Mouse (sf9, His-GST)
Tyrosine-protein kinase CSK; C-Src kinase; CSK
Mouse Sf9 insect cells

HY-P70109

CDCP1 Protein, Human (313a.a, HEK293, His) rHuCUB domain-containing protein 1/CDCP1, His; CUB domain-containing protein 1; Membrane glycoprotein gp140; Subtractive immunization M plus HEp3-associated 135 kDa protein; SIMA135; Transmembrane and associated with Src kinases; CD318; TRASK	Human	HEK293

Cat. No.	Product Name

HY-12047S

Ponatinib-d8
Ponatinib-d₈ is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-10181S

Dasatinib-d8

Dasatinib-d₈ is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.
HY-10158S

Bosutinib D8

Bosutinib-d₈ is a deuterium labeled Bosutinib. Bosutinib is a dual Src/Abl inhibitor with IC50s of 1.2 nM and 1 nM, respectively[1][2].

HY-133794S

Dasatinib N-oxide-d8
Dasatinib N-oxide-d₈ is the deuterium labeled Dasatinib N-oxide. Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor[1][2].

HY-10230S

Midostaurin-d5
Midostaurin-d₅ is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM[1].

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base[1]. Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the treatment of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[2][3][4].

Src

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products